Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

• Status: Completed
• Trial end date: 2015-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to compare the short-term and long-term efficacies and the safeties of pirarubicin plus docetaxel(AT group) and pirarubicin plus cyclophosphamide followed by docetaxel(AC-T group) in neoadjuvant chemotherapy of breast cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: 307 Hospital of PLA
• Treatments: Cyclophosphamide; Docetaxel; Pirarubicin

Criteria

Inclusion Criteria:

• histopathologically diagnosed with stage I-III breast cancers;

• clearly confirmed ER, PR and HER2 statuses;

• the state of axillary lymph nodes was determined through the relevant examination steps (puncture or sentinel lymph node biopsy);

• the patients were not treated with neoadjuvant therapy and surgery.

Exclusion Criteria:

• the patients whose breasts or axillary lumps had received excision biopsy;

• the patients who had severely abnormal organ functions or who could not tolerate chemotherapy,

• the patients with severe concomitant diseases;

• the patients with heart disease or left ventricular ejection fraction (LVEF) <50%.